ERICA LEE: Open Payments
NPI 1013506740 · FULLERTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,509 in 75 payments from 18 companies in 2025. Trend: 2023 $1,323 · 2024 $1,649 · 2025 $1,509
Food & beverage: $1,509
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 13 | $259 |
| Janssen Biotech, Inc. | 12 | $254 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $160 |
| Lilly USA, LLC | 9 | $156 |
| GENZYME CORPORATION | 6 | $150 |
| Gilead Sciences, Inc. | 5 | $120 |
| Intercept Pharmaceuticals, Inc. | 5 | $84 |
| Ipsen Biopharmaceuticals, Inc | 2 | $67 |
| Fresenius Kabi USA, LLC | 2 | $64 |
| Madrigal Pharmaceuticals | 2 | $36 |
Products named: IBSRELA, TREMFYA, XIFAXAN, DUPIXENT, OCALIVA, IQIRVO, OMVOH, REZDIFFRA.
Industry payments across CA — which companies pay providers there.
